Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 4 25 IN DEXTROSE 25 IN PLASTIC CONTAINER versus TRAVASOL 5 5 W O ELECTROLYTES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 4 25 IN DEXTROSE 25 IN PLASTIC CONTAINER versus TRAVASOL 5 5 W O ELECTROLYTES.
AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER vs TRAVASOL 5.5% W/O ELECTROLYTES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosin II 4.25% in Dextrose 25% provides essential amino acids and dextrose for parenteral nutrition. Amino acids serve as building blocks for protein synthesis, while dextrose supplies a source of calories to prevent catabolism. The combination aims to maintain nitrogen balance and support metabolic functions.
TRAVASOL 5.5% W/O ELECTROLYTES is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, tissue repair, and nitrogen balance in patients unable to tolerate enteral nutrition. It serves as a substrate for gluconeogenesis and other metabolic processes.
Administer as a continuous intravenous infusion. Typical adult dose: 1.0-1.5 g amino acids/kg/day (equivalent to approximately 23-35 mL/kg/day of AMINOSYN II 4.25% in DEXTROSE 25%) via central venous line. Adjust based on metabolic needs and tolerance.
Intravenous infusion, 500 mL to 2000 mL per day as a component of total parenteral nutrition (TPN), providing 5.5% amino acids. Rate should be individualized based on metabolic requirements and tolerance.
None Documented
None Documented
Amino acids: 0.5-2 hours; dextrose: 1-4 hours in non-diabetic patients; context: reflects rapid uptake and metabolism
Not applicable as a fixed drug; the clearance of infused amino acids follows saturable kinetics with a functional half-life of approximately 30-60 minutes for free amino acids in plasma, reflecting rapid uptake and metabolism. Clinical context: continuous infusion maintains steady-state levels.
Renal: >90% as amino acids and metabolites; biliary/fecal: minimal (<2%)
Primarily renal excretion of amino acids and metabolites; approximately 70-80% of infused amino acids are converted to urea and excreted in urine, with the remainder undergoing metabolism or incorporation into body proteins. Biliary/fecal excretion is negligible.
Category C
Category C
Amino Acid Solution
Amino Acid Solution